# A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

> **NCT07705334** · PHASE1 · RECRUITING · sponsor: **SHY Therapeutics** · enrollment: 30 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors
- Triple Negative Breast Cancer (TNBC)
- HR+ Breast Cancer
- Colon Cancer
- Gastric Cancer
- Hepatecellular Carcinoma
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Mesothelioma
- Pancreatic Carcinoma Metastatic
- Hormone Refractory Prostate Cancer
- Soft Tissue Sarcomas

## Interventions

- **DRUG:** SHY-ONC6

## Key facts

- **NCT ID:** NCT07705334
- **Lead sponsor:** SHY Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-24
- **Primary completion:** 2027-05-15
- **Final completion:** 2028-05-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07705334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07705334, "A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07705334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*